-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naptumomab Estafenatox in Metastatic Prostate Cancer Drug Details:ABR-217620 (anyara, naptumomab estafenatox)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Epithelial Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naptumomab Estafenatox in Epithelial Ovarian Cancer Drug Details:ABR-217620 (anyara, naptumomab estafenatox)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC) Drug Details:ABR-217620 (anyara,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naptumomab Estafenatox in Metastatic Ovarian Cancer Drug Details:ABR-217620 (anyara, naptumomab estafenatox)...
-
Company Profile
Active Biotech AB – Company Profile
Active Biotech AB (Active Biotech) is a biotechnology company that focuses on the development of therapeutics in the field of cancer, inflammatory eye disorders and neurodegenerative diseases. The company’s pipeline products include naptumomab for the treatment of solid tumors and lung cancer; tasquinimod for multiple myeloma; and laquinimod for the Uveitis. The portfolio comprises of antibody-based immunotherapy and small, orally active immunomodulatory molecules. It has partnerships with NeoTX Therapeutics Ltd and with the Perelman School of Medicine, University of Pennsylvania....
Add to Basket -
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...